13-51946291-G-A
Position:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM2PP3_ModeratePP5_Very_Strong
The NM_000053.4(ATP7B):c.3053C>T(p.Ala1018Val) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000341 in 1,585,058 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.000026 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000035 ( 0 hom. )
Consequence
ATP7B
NM_000053.4 missense
NM_000053.4 missense
Scores
12
4
3
Clinical Significance
Conservation
PhyloP100: 9.93
Genes affected
ATP7B (HGNC:870): (ATPase copper transporting beta) This gene is a member of the P-type cation transport ATPase family and encodes a protein with several membrane-spanning domains, an ATPase consensus sequence, a hinge domain, a phosphorylation site, and at least 2 putative copper-binding sites. This protein is a monomer, and functions as a copper-transporting ATPase which exports copper out of the cells, such as the efflux of hepatic copper into the bile. Alternate transcriptional splice variants, encoding different isoforms with distinct cellular localizations, have been characterized. Mutations in this gene have been associated with Wilson disease which is characterized by copper accumulation. [provided by RefSeq, Dec 2019]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.894
PP5
Variant 13-51946291-G-A is Pathogenic according to our data. Variant chr13-51946291-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 188722.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr13-51946291-G-A is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATP7B | NM_000053.4 | c.3053C>T | p.Ala1018Val | missense_variant | 13/21 | ENST00000242839.10 | NP_000044.2 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152216Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
4
AN:
152216
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000584 AC: 12AN: 205324Hom.: 0 AF XY: 0.0000631 AC XY: 7AN XY: 110960
GnomAD3 exomes
AF:
AC:
12
AN:
205324
Hom.:
AF XY:
AC XY:
7
AN XY:
110960
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000349 AC: 50AN: 1432842Hom.: 0 Cov.: 31 AF XY: 0.0000338 AC XY: 24AN XY: 710260
GnomAD4 exome
AF:
AC:
50
AN:
1432842
Hom.:
Cov.:
31
AF XY:
AC XY:
24
AN XY:
710260
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152216Hom.: 0 Cov.: 33 AF XY: 0.0000134 AC XY: 1AN XY: 74376
GnomAD4 genome
AF:
AC:
4
AN:
152216
Hom.:
Cov.:
33
AF XY:
AC XY:
1
AN XY:
74376
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
TwinsUK
AF:
AC:
1
ALSPAC
AF:
AC:
1
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
1
ExAC
AF:
AC:
5
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Wilson disease Pathogenic:8
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 17, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 16, 2023 | Variant summary: ATP7B c.3053C>T (p.Ala1018Val) results in a non-conservative amino acid change located in the P-type ATPase, haloacid dehalogenase domain (IPR044492) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 5.8e-05 in 205324 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in ATP7B causing Wilson Disease (5.8e-05 vs 0.0054). c.3053C>T has been reported in the literature in multiple individuals affected with Wilson Disease (Loudianos_1998, Vrabelova_2005, Dong_2016, Singh_2019, Couchonnal_2021, etc.). These data indicate that the variant is very likely to be associated with disease. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. The 4 laboratories classified the variant as likely pathogenic (n=2), or pathogenic (n=2). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 21, 2024 | - - |
Likely pathogenic, criteria provided, single submitter | literature only | Counsyl | Mar 17, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Aug 05, 2024 | This missense variant replaces alanine with valine at codon 1018 in the P domain of the ATP7B protein (a.a. 1004 - 1031), a highly conserved region that is considered to be important for ATP7B protein function (PMID: 35245129; ClinVar). Computational prediction suggests that this variant may have deleterious impact on protein structure and function. Functional studies have reported that this variant resulted in reduced protein levels and decreased copper export capacity (PMID: 37157876). This variant has been observed in many individuals affected with autosomal recessive Wilson disease, with some cases confirmed in the compound heterozygous state (PMID: 9671269, 10502776, 15967699, 17154398, 17949296, 18034201, 22677543, 24146181, 24718822, 27022412, 30884209, 31059521, 33640437, 34400371, 35535059; ClinVar SCV000948175.5), indicating that this variant contributes to disease. This variant has been identified in 12/205324 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 12, 2023 | This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 1018 of the ATP7B protein (p.Ala1018Val). This variant is present in population databases (rs371840514, gnomAD 0.01%). This missense change has been observed in individual(s) with Wilson disease (PMID: 17154398, 30884209, 31059521; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 188722). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ATP7B protein function with a negative predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Mar 09, 2022 | The ATP7B c.3053C>T; p.Ala1018Val variant (rs371840514) is reported in the literature in several individuals affected with Wilson disease, including in the compound heterozygous state with other pathogenic ATP7B variants (Lepori 2007, Loudianos 1998, Mak 2008, Petrasek 2007, Qian 2019, Singh 2019, Vrabelova 2005, Zappu 2008). This variant is also reported in ClinVar (Variation ID: 188722), and is found in the general population with an overall allele frequency of 0.0058% (12/205324 alleles) in the Genome Aggregation Database. The alanine at codon 1018 is moderately conserved, and computational analyses predict that this variant is deleterious (REVEL: 0.890). Based on available information, this variant is considered to be pathogenic. References: Lepori MB et al. Twenty-four novel mutations in Wilson disease patients of predominantly Italian origin. Genet Test. 2007 Fall;11(3):328-32. PMID: 17949296. Loudianos G et al. Further delineation of the molecular pathology of Wilson disease in the Mediterranean population. Hum Mutat. 1998;12(2):89-94. PMID: 9671269. Mak CM et al. Mutational analysis of 65 Wilson disease patients in Hong Kong Chinese: identification of 17 novel mutations and its genetic heterogeneity. J Hum Genet. 2008;53(1):55-63. PMID: 18034201. Petrasek J et al. Revised King's College score for liver transplantation in adult patients with Wilson's disease. Liver Transpl. 2007 Jan;13(1):55-61. PMID: 17154398. Qian Z et al. Novel mutations found in the ATP7B gene in Chinese patients with Wilson's disease. Mol Genet Genomic Med. 2019 May;7(5):e649. PMID: 30884209. Singh N et al. Genetic analysis of ATP7B in 102 south Indian families with Wilson disease. PLoS One. 2019 May 6;14(5):e0215779. PMID: 31059521. Vrabelova S et al. Mutation analysis of the ATP7B gene and genotype/phenotype correlation in 227 patients with Wilson disease. Mol Genet Metab. 2005 Sep-Oct;86(1-2):277-85. PMID: 15967699. Zappu A et al. High incidence and allelic homogeneity of Wilson disease in 2 isolated populations: a prerequisite for efficient disease prevention programs. J Pediatr Gastroenterol Nutr. 2008 Sep;47(3):334-8. PMID: 18728530. - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Aug 10, 2021 | - - |
ATP7B-related disorder Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Oct 06, 2023 | The ATP7B c.3053C>T variant is predicted to result in the amino acid substitution p.Ala1018Val. This variant has been reported in several individuals with Wilson disease, though clinical and variant phase data was not well documented in some of these individuals (Loudianos et al. 1998. PubMed ID: 9671269; Table S2, Schushan et al. 2012. PubMed ID: 22692182; Couchonnal et al. 2021. PubMed ID: 34400371; Table S4, Zhang et al. 2022. PubMed ID: 35220961; Mak et al. 2007. PubMed ID: 18034201; Petrasek et al. 2007. PubMed ID: 17154398; Singh et al. 2019. PubMed ID: 31059521; Dong et al. 2016. PubMed ID: 27022412). However, in at least 2 individuals, clinical, laboratory and histological findings were consistent with Wilson disease; including one individual diagnosed with later onset Wilson disease who was homozygous for the variant (Stalke et al. 2023. PubMed ID: 37157876, Annamalai et al. 2022. PubMed ID: 35580721). In vitro functional studies demonstrate this variant leads to a not statistically significant reduced protein levels and reduced copper export capacity, but in similar range to a well established pathogenic missense variant (Stalke et al. 2023. PubMed ID: 37157876). This variant is reported in 0.011% of alleles in individuals of South Asian descent in gnomAD (http://gnomad.broadinstitute.org/variant/13-52520427-G-A). We classify this variant as likely pathogenic. - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 04, 2021 | Reported in multiple individuals with Wilson disease with no information provided regarding the presence of a second ATP7B variant (Loudianos et al., 1998; Loudianos et al., 1999; Vrabelova et al., 2005; Lepori et al., 2007; Zappu et al., 2008; Mak et al., 2008; Chen et al., 2019); Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 30275481, 31246682, 30655162, 17949296, 22692182, 17154398, 18034201, 23486543, 18728530, 15967699, 10502776, 9671269, 30556376, 30884209) - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Pathogenic
D;T;.;.;.;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Pathogenic
D;D;D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Uncertain
M;.;.;.;.;.
PrimateAI
Pathogenic
D
PROVEAN
Uncertain
D;D;D;D;D;.
REVEL
Pathogenic
Sift
Benign
T;D;T;T;D;.
Sift4G
Uncertain
T;D;T;T;T;D
Polyphen
D;D;D;B;D;D
Vest4
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at